Previous 10 | Next 10 |
Shares of pharma giant AbbVie (NYSE: ABBV) dipped by 3.96% over the course of 2019, according to data from S&P Global Market Intelligence . The drugmaker's stock slipped last year for two fundamental reasons: Prior to 2019, AbbVie's shares had appreciated by a whopping 163% s...
AbbVie (NYSE: ABBV) shareholders didn't have a lot to get excited about last year. The stock finished 2019 down 4%, while the S&P 500 surged 29%. But the big drugmaker's future is a lot more important than its past. Rick Gonzalez, AbbVie's CEO, along with a couple of other top exe...
DUBLIN , Jan. 16, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced today a partnership with Von Miller , Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, to shine a ...
AbbVie ( ABBV ) reported that it has received conditional approval in Europe for its proposed merger with Allergan (AGN). The $63 billion merger has been closely watched by international regulatory authorities. It is likely that after Europe, the US may also give the green signal to the merg...
AbbVie (NYSE: ABBV) could be poised for a great year. The company will close its acquisition of drug manufacturer Allergan (NYSE: AGN) early this year, which will help pad AbbVie's results, add more products into its portfolio, and diversify its revenue stream by adding more br...
ETF Overview iShares U.S. Pharmaceuticals ETF ( IHE ) owns a portfolio of large-cap pharmaceutical stocks. The ETF tracks the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. Stocks in IHE's portfolio are stocks with competitive advantages over their smaller peers. In a...
Newport Beach, California-based Evolus (NASDAQ: EOLS ) is the newest entrant in the injectable aesthetics market. The business is strategized around a single product, a botulinum toxin marketed as Jeuveau. Their strategy focuses solely on the self-pay portion of the market, which we see as a l...
It was more of the same in the stock market last week in terms of returns, but the catalysts supporting the rally shifted from easing trade tensions and dovish Federal Reserve policy to a deescalating of tensions between the U.S. and Iran. Specifically, a tepid Iranian response to the U.S. str...
When you're managing your own retirement planning, every dollar invested and every transaction is important. And every dividend is important when you are planning on using the dividends that your portfolio produces to cover expenses once you reach retirement. This approach takes time: time t...
As AbbVie (NYSE: ABBV) gets closer to completing its $63 billion acquisition of Allergan (NYSE: AGN) , the company is laying out its plan for the integration. When the deal closes, which is scheduled to happen this quarter, AbbVie will keep Allergan's aesthetics as a separate unit with ...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET About to begin a phase 2b/3 multinational study of Ifenprodil Algernon Pharmaceuticals is a drug repurposing company. They're a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential thera...
2024-03-27 17:08:02 ET A stroke can be a devastating and debilitating event for an individual and their family, and a major burden on the health care system. Over 15 million people suffer strokes every year, and 85% of those have some form of disability as a result. Stroke-related cos...
2024-03-27 17:08:02 ET Stocks to Invest in: Healthcare Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease Algernon is a drug re-purposing company that investigates safe, already approved drugs, inclu...